お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
989539

抗糖尿病薬市場規模調査:タイプ別(アルファ-グルコシダーゼ阻害剤、ビグアニド、DPP-IV阻害剤、GLP-1アゴニスト、およびインスリン)、疾患別、患者別(~2025年)、COVID-19の累積的影響

Antidiabetic Drug Market Research Report by Type (Alpha-glucosidase Inhibitors, Biguanides, DPP-IV Inhibitors, GLP-1 Agonists, and Insulin), by Disease, by Patient - Global Forecast to 2025 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.25円
抗糖尿病薬市場規模調査:タイプ別(アルファ-グルコシダーゼ阻害剤、ビグアニド、DPP-IV阻害剤、GLP-1アゴニスト、およびインスリン)、疾患別、患者別(~2025年)、COVID-19の累積的影響
出版日: 2021年02月11日
発行: 360iResearch LLP
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗糖尿病薬の市場規模は、2020年の352億9817万米ドルから、2025年末までに561億4671万米ドルに成長すると予想されています。

市場セグメンテーションとカバレッジ

当調査は、抗糖尿病薬の世界市場を分類して、収益を予測し、次の各サブマーケットの動向を分析します。

  • タイプ別では、抗糖尿病薬市場は、アルファ-グルコシダーゼ阻害剤、ビグアニド、DPP-IV(ジペプチジルペプチダーゼ)阻害剤、GLP-1(グルカゴン様ペプチド)アゴニスト、インスリン、メグリチニド、SGLT-II(ナトリウムグルコース輸送タンパク質)阻害剤、スルホニル尿素、およびチアゾリジンジオンにわたって調査されました。インスリンは、中間作用型インスリン、長時間作用型アナログ、プレミックスインスリン、速効型アナログ、および短時間作用型アナログにわたってさらに調査されました。
  • 病気別では、糖尿病治療薬市場は1型糖尿病と2型糖尿病の間で調査されました。
  • 患者別では、抗糖尿病薬市場は成人、老年、および小児全体で調査されました。
  • 地域別では、抗糖尿病薬市場は南北アメリカ、アジア太平洋、欧州、中東・アフリカ、アルゼンチン、ブラジル、カナダ、メキシコ、および米国で調査されました。アジア太平洋地域ではオーストラリア、中国、インド、インドネシア、日本、マレーシア、フィリピン、韓国、タイで調査されました。欧州、中東、およびアフリカ地域ではフランス、ドイツ、イタリア、オランダ、カタール、ロシア、サウジアラビア、南アフリカ、スペイン、アラブ首長国連邦、および英国全体で調査されました。

COVID-19の累積的影響

COVID-19は、ほぼすべての業界に影響を与えた比類のない世界的な公衆衛生上の緊急事態であるため、予測期間中に業界の成長に長期的な影響を与えると予測されます。私たちの進行中の調査は、調査フレームワークを増幅して、基礎となるCOVID-19の問題と今後の潜在的な道筋を確実に含めるようにしています。調査は消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場の力のダイナミクス、および政府の重要な介入を考慮したCOVID-19に関する洞察を提供しています。更新された調査は、市場へのCOVID-19の影響を考慮して、洞察、分析、推定、および予測を提供します。

レポートは、次の指針に関する洞察を提供します。

  • 1.市場浸透:主要なプレーヤーにより提供される市場に関する包括的な情報
  • 2.市場開発:収益性の高い新興市場に関する詳細な情報と市場分析
  • 3.市場の多様化:新製品の発売、未開発の地域、最近の開発、および投資に関する詳細情報
  • 4.競争力のある評価とインテリジェンス:主要企業の市場シェア、戦略、製品、製造能力の徹底的な評価を提供します
  • 5.製品開発とイノベーション:将来のテクノロジー、R&D活動、および新製品開発に関する洞察

レポートは次のような質問に答えます。

  • 1.世界の抗糖尿病薬市場の市場規模と予測はどのくらいですか?
  • 2.予測期間中に世界の抗糖尿病薬市場を形成するCOVID-19の阻害要因と影響は何ですか?
  • 3.世界の糖尿病治療薬市場の予測期間中に投資する製品/セグメント/アプリケーション/領域はどれですか?
  • 4.世界の抗糖尿病薬市場における機会の競争戦略的ウィンドウは何ですか?
  • 5.世界の糖尿病治療薬市場動向技術動向と規制の枠組みは何ですか?
  • 6.世界の糖尿病治療薬市場に参入するのに適していると考えられるモードと戦略的動きは何ですか?

当レポートでは、抗糖尿病薬市場を調査し、市場概要、市場の成長要因および阻害要因の分析、タイプ別・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイル、市場機会など、包括的な情報を提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画を作成する
    • 実行:調査を実施する
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • イントロダクション
  • 市場別見通し
  • 患者別見通し
  • タイプ別見通し
  • 病気別見通し
  • 地域別展望
  • 競合他社別見通し

第4章 市場概要

  • イントロダクション
  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 タイプ別の世界の糖尿病治療薬市場

  • イントロダクション
  • アルファ-グルコシダーゼ阻害剤
  • ビグアニド
  • DPP-IV(ジペプチジルペプチダーゼ)阻害剤
  • GLP-1(グルカゴン様ペプチド)アゴニスト
  • インスリン
    • 中間作用型インスリン
    • 長時間作用型アナログ
    • プレミックスインスリン
    • 速効型アナログ
    • 短時間作用型アナログ
  • メグリチニド
  • SGLT-II(ナトリウムグルコース輸送タンパク質)阻害剤
  • スルホニル尿素剤
  • チアゾリジンジオン

第7章 世界の抗糖尿病薬市場:疾患別

  • イントロダクション
  • 1型糖尿病
  • 2型糖尿病

第8章 世界の糖尿病治療薬市場:患者別

  • イントロダクション
  • 大人
  • 老年医学
  • 小児科

第9章 南北アメリカの抗糖尿病薬市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の糖尿病治療薬市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第11章 欧州、中東・アフリカの糖尿病治療薬市場

  • イントロダクション
  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第13章 企業のユーザビリティプロファイル

  • Abbott Laboratories
  • Aristo Pharmaceuticals Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • C.H. Boehringer Sohn AG & Co. KG
  • Cadila Pharmaceuticals Limited
  • Cipla, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
  • Mankind Pharma Ltd
  • Merck KGaA
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • PHC Corporation
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
  • Wockhardt Limited

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

List of Figures

  • FIGURE 1. GLOBAL ANTIDIABETIC DRUG MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL ANTIDIABETIC DRUG MARKET: RESEARCH EXECUTION
  • FIGURE 3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2020 VS 2025 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2018-2025 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 12. GLOBAL ANTIDIABETIC DRUG MARKET: MARKET DYNAMICS
  • FIGURE 13. GLOBAL ANTIDIABETIC DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 VS 2025 (%)
  • FIGURE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 VS 2025 (USD MILLION)
  • FIGURE 16. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2025
  • FIGURE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, 2020 VS 2025 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, 2020 VS 2025 (USD MILLION)
  • FIGURE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, 2020 VS 2025 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, 2020 VS 2025 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, 2020 VS 2025 (USD MILLION)
  • FIGURE 22. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, 2020 VS 2025 (USD MILLION)
  • FIGURE 23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, 2020 VS 2025 (USD MILLION)
  • FIGURE 24. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, 2020 VS 2025 (USD MILLION)
  • FIGURE 25. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, 2020 VS 2025 (USD MILLION)
  • FIGURE 26. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, 2020 VS 2025 (USD MILLION)
  • FIGURE 27. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, 2020 VS 2025 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, 2020 VS 2025 (USD MILLION)
  • FIGURE 29. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, 2020 VS 2025 (USD MILLION)
  • FIGURE 30. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, 2020 VS 2025 (USD MILLION)
  • FIGURE 31. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 VS 2025 (%)
  • FIGURE 32. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 VS 2025 (USD MILLION)
  • FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2025
  • FIGURE 34. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, 2020 VS 2025 (USD MILLION)
  • FIGURE 35. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, 2020 VS 2025 (USD MILLION)
  • FIGURE 36. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 VS 2025 (%)
  • FIGURE 37. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 VS 2025 (USD MILLION)
  • FIGURE 38. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2025
  • FIGURE 39. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, 2020 VS 2025 (USD MILLION)
  • FIGURE 40. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, 2020 VS 2025 (USD MILLION)
  • FIGURE 41. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, 2020 VS 2025 (USD MILLION)
  • FIGURE 42. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 43. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 44. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 45. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 46. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 47. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 48. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 49. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 50. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 51. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 52. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 53. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 54. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 55. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 56. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 57. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 58. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 59. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 60. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 61. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 62. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 63. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 64. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 65. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 66. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 67. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 68. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 69. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 70. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 71. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 72. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 73. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 74. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 75. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 76. GLOBAL ANTIDIABETIC DRUG MARKET: 360IRESEARCH™ FPNV POSITIONING MATRIX
  • FIGURE 77. GLOBAL ANTIDIABETIC DRUG MARKET: 360IRESEARCH™ MARKET SHARE ANALYSIS
  • FIGURE 78. GLOBAL ANTIDIABETIC DRUG MARKET: COMPETITOR SWOT ANALYSIS
  • FIGURE 79. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTIDIABETIC DRUG MARKET, BY TYPE

List of Tables

  • TABLE 1. CURRENCY CONVERSION RATES
  • TABLE 2. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. GLOBAL ANTIDIABETIC DRUG MARKET: SCORES
  • TABLE 114. GLOBAL ANTIDIABETIC DRUG MARKET: BUSINESS STRATEGY
  • TABLE 115. GLOBAL ANTIDIABETIC DRUG MARKET: PRODUCT SATISFACTION
  • TABLE 116. GLOBAL ANTIDIABETIC DRUG MARKET: RANKING
  • TABLE 117. GLOBAL ANTIDIABETIC DRUG MARKET: MERGER & ACQUISITION
  • TABLE 118. GLOBAL ANTIDIABETIC DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 119. GLOBAL ANTIDIABETIC DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 120. GLOBAL ANTIDIABETIC DRUG MARKET: INVESTMENT & FUNDING
  • TABLE 121. GLOBAL ANTIDIABETIC DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 122. GLOBAL ANTIDIABETIC DRUG MARKET: LICENSE & PRICING
目次
Product Code: MRR-6AA367B

Title:
Antidiabetic Drug Market Research Report by Type (Alpha-glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors, GLP-1 (Glucagon-like Peptide) Agonists, and Insulin), by Disease (Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2), by Patient - Global Forecast to 2025 - Cumulative Impact of COVID-19.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

  • 1. The Global Antidiabetic Drug Market is expected to grow from USD 35,298.17 Million in 2020 to USD 56,146.71 Million by the end of 2025.
  • 2. The Global Antidiabetic Drug Market is expected to grow from EUR 30,950.10 Million in 2020 to EUR 49,230.50 Million by the end of 2025.
  • 3. The Global Antidiabetic Drug Market is expected to grow from GBP 27,514.71 Million in 2020 to GBP 43,766.02 Million by the end of 2025.
  • 4. The Global Antidiabetic Drug Market is expected to grow from JPY 3,767,209.19 Million in 2020 to JPY 5,992,276.71 Million by the end of 2025.
  • 5. The Global Antidiabetic Drug Market is expected to grow from AUD 51,257.63 Million in 2020 to AUD 81,532.49 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Antidiabetic Drug to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Type, the Antidiabetic Drug Market studied across Alpha-glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors, GLP-1 (Glucagon-like Peptide) Agonists, Insulin, Meglitinides, SGLT-II (Sodium Glucose Transport Proteins) Inhibitors, Sulphonylureas, and Thiazolidinedione. The Insulin further studied across Intermediate-acting Insulin, Long-acting Analog, Premixed Insulin, Rapid-acting Analog, and Short-acting Analog.
  • Based on Disease, the Antidiabetic Drug Market studied across Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2.
  • Based on Patient, the Antidiabetic Drug Market studied across Adult, Geriatric, and Pediatric.
  • Based on Geography, the Antidiabetic Drug Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Antidiabetic Drug Market including Abbott Laboratories, Aristo Pharmaceuticals Pvt. Ltd., Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, C.H. Boehringer Sohn AG & Co. KG, Cadila Pharmaceuticals Limited, Cipla, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals), Mankind Pharma Ltd, Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., PHC Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., TONGHUA DONGBAO PHARMACEUTICAL CO., LTD., and Wockhardt Limited.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch™ FPNV Positioning Matrix:

The 360iResearch™ FPNV Positioning Matrix evaluates and categorizes the vendors in the Antidiabetic Drug Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch™ Competitive Strategic Window:

The 360iResearch™ Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch™ Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Antidiabetic Drug Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antidiabetic Drug Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antidiabetic Drug Market?
  • 4. What is the competitive strategic window for opportunities in the Global Antidiabetic Drug Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Antidiabetic Drug Market?
  • 6. What are the modes and strategic moves considered suitable for entering the Global Antidiabetic Drug Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Define: Research Objective
    • 2.1.2. Determine: Research Design
    • 2.1.3. Prepare: Research Instrument
    • 2.1.4. Collect: Data Source
    • 2.1.5. Analyze: Data Interpretation
    • 2.1.6. Formulate: Data Verification
    • 2.1.7. Publish: Research Report
    • 2.1.8. Repeat: Report Update
  • 2.2. Research Execution
    • 2.2.1. Initiation: Research Process
    • 2.2.2. Planning: Develop Research Plan
    • 2.2.3. Execution: Conduct Research
    • 2.2.4. Verification: Finding & Analysis
    • 2.2.5. Publication: Research Report
  • 2.3. Research Outcome

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Patient Outlook
  • 3.4. Type Outlook
  • 3.5. Disease Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Changing lifestyle of people and irregular dietary habits
      • 5.1.1.2. Strong product pipeline of antidiabetics
      • 5.1.1.3. Globally rising prevalence of diabetes and increasing obesity among people
      • 5.1.1.4. Increasing consumer awareness level and improved technology
    • 5.1.2. Restraints
      • 5.1.2.1. Prohibitive cost of Insulin
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in the healthcare and pharmaceutical sectors
      • 5.1.3.2. Ongoing research and development
      • 5.1.3.3. Governments and private companies to work together for the supply of inexpensive drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Wide availability of antidiabetics drugs
  • 5.2. Porters Five Forces Analysis
    • 5.2.1. Threat of New Entrants
    • 5.2.2. Threat of Substitutes
    • 5.2.3. Bargaining Power of Customers
    • 5.2.4. Bargaining Power of Suppliers
    • 5.2.5. Industry Rivalry

6. Global Antidiabetic Drug Market, By Type

  • 6.1. Introduction
  • 6.2. Alpha-glucosidase Inhibitors
  • 6.3. Biguanides
  • 6.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
  • 6.5. GLP-1 (Glucagon-like Peptide) Agonists
  • 6.6. Insulin
    • 6.6.1. Intermediate-acting Insulin
    • 6.6.2. Long-acting Analog
    • 6.6.3. Premixed Insulin
    • 6.6.4. Rapid-acting Analog
    • 6.6.5. Short-acting Analog
  • 6.7. Meglitinides
  • 6.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
  • 6.9. Sulphonylureas
  • 6.10. Thiazolidinedione

7. Global Antidiabetic Drug Market, By Disease

  • 7.1. Introduction
  • 7.2. Diabetes Mellitus Type 1
  • 7.3. Diabetes Mellitus Type 2

8. Global Antidiabetic Drug Market, By Patient

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Americas Antidiabetic Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antidiabetic Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. South Korea
  • 10.10. Thailand

11. Europe, Middle East & Africa Antidiabetic Drug Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis
  • 12.4. Competitor SWOT Analysis
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. Abbott Laboratories
  • 13.2. Aristo Pharmaceuticals Pvt. Ltd.
  • 13.3. Astellas Pharma Inc.
  • 13.4. AstraZeneca PLC
  • 13.5. Biocon Limited
  • 13.6. C.H. Boehringer Sohn AG & Co. KG
  • 13.7. Cadila Pharmaceuticals Limited
  • 13.8. Cipla, Inc.
  • 13.9. Eli Lilly and Company
  • 13.10. F. Hoffmann-La Roche Ltd.
  • 13.11. GlaxoSmithKline PLC
  • 13.12. Glenmark Pharmaceuticals Ltd.
  • 13.13. Halozyme Therapeutics, Inc.
  • 13.14. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
  • 13.15. Mankind Pharma Ltd
  • 13.16. Merck KGaA
  • 13.17. Novo Nordisk A/S
  • 13.18. Oramed Pharmaceuticals Inc.
  • 13.19. Pfizer Inc.
  • 13.20. PHC Corporation
  • 13.21. Sanofi S.A.
  • 13.22. Takeda Pharmaceutical Company Limited
  • 13.23. Teva Pharmaceutical Industries Ltd.
  • 13.24. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
  • 13.25. Wockhardt Limited

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.